Close Menu

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a UK distribution agreement for its SelectMDx prostate cancer test with Lab21.

Under the terms of the deal, Lab21 will serve as a non-exclusive distributor of the test in the UK, and send liquid biopsy samples to MDxHealth's clinical diagnostic lab in The Netherlands for analysis. Lab21 will reimburse MDxHealth for all testing services performed.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.